WENDY STARNES: Open Payments
NPI 1992110761 · MARSHALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,130 in 57 payments from 14 companies in 2025. Trend: 2023 $1,284 · 2024 $978 · 2025 $1,130
Food & beverage: $1,130
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $232 |
| AstraZeneca Pharmaceuticals LP | 7 | $218 |
| ABBVIE INC. | 8 | $181 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $175 |
| Lilly USA, LLC | 5 | $86 |
| Amgen Inc. | 4 | $66 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
Products named: Kerendia, VRAYLAR, Ozempic, BREZTRI, JARDIANCE, Rybelsus, FARXIGA, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
